Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Grifols, S.A.NASDAQ: GRFS

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows in line with its trailing trend

Q2 FY2026 cost of revenue of €1.17B rose 2.0% year over year, behind the +3.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Cost of revenue amounted to 64.3% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.0% toward the trailing-twelve-month pace of +3.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€1.17B+6.6% QoQ
Last fiscal yearDec 2025
€4.65B+5.2% YoY
LTMJun 2026
€4.66B+3.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year+5.2%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
4.65B EUR
Year-over-year change
+5.2%
4-year CAGR
+11.8%

Cost of Revenue vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.6% is the highest of 9, against a peer median of -0.6%.
  • Cost of revenue amounts to 62.8% of revenue for GRFS, versus a peer median of 45.5%.
GRFS Competitors
Cost of Revenue for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$20.68B USD+2.5%-2.6%42.9%
BDXBecton, Dickinson and CompanyLTM Sep 2026$10.72B USD-10.1%-2.9%53.0%
GRFSGrifols, S.A.LTM Jun 2026€4.66B EUR+3.6%+6.5%62.8%
QDELQuidelOrtho CorporationLTM Mar 2026$1.46B USD-0.3%+3.1%55.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$1.25B USD+3.4%+0.1%48.1%
HAEHaemonetics CorporationLTM Jun 2026$576.17M USD-0.9%+2.7%42.6%
TECHBio-Techne CorporationLTM Sep 2026$420.61M USD-0.2%+4.3%34.2%
ADMAADMA Biologics, Inc.LTM Jun 2026$180.81M USD-18.9%+22.3%35.3%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$136.53M USD-10.8%-3.4%65.4%
Peer median (excluding GRFS) —-0.6%+1.4%45.5%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.